基于小分子多肽放射性药物临床应用研究现状与挑战  

Current Situation and Challenge of Clinical Application of Based Small Molecular Peptide Radiopharmaceuticals

作　　者：王荣福[1,2] 杜毓菁 WANG Rong-fu;DU Yu-jing(Department of Nuclear Medicine,Peking University First Hospital,Beijing 100034,China;Department of Nuclear Medicine,Peking University International Hospital,Beijing 102206,China)

机构地区：[1]北京大学第一医院核医学科,北京100034 [2]北京大学国际医院核医学科,北京102206

出　　处：《核化学与放射化学》2020年第3期129-137,I0002,共10页Journal of Nuclear and Radiochemistry

基　　金：北京市科技计划项目(首都健康保障培育研究专项课题,Z181100001618017);国家重大科学仪器设备开发专项(2011YQ03011409);十二五国家支撑项目基金(2014BAA03B03);北京大学医学青年科技创新平台发展基金(BMU2018MI010)。

摘　　要：放射性药物是核科学技术在医学应用上的重要基石之一。我国放射性药物临床转化应用研究较国外发展较为滞后,且自身存在一定问题,研发具有我国自主知识产权并具有临床应用前景的新型放射性药物势在必行。本文回顾了我国放射性药物的应用现状,通过横向比较和纵向分析我国放射性药物发展的潜在共性问题,结合当前小分子多肽放射性药物应用研究呈不同程度持续推进的临床转化工作,针对存在问题深层次剖析,并提出了研发具有应用前景和临床转化的新型诊治放射性药物的重要性和必要性。Radiopharmaceuticals are one of the important cornerstones of nuclear science and technology in medical application. The research on clinical transformation and application of radiopharmaceuticals in China lags behind that in foreign countries, and there are some problems in our country. It is imperative to develop new radiopharmaceuticals with independent intellectual property rights and clinical application prospects. This paper reviews the current situation of the application of radiopharmaceuticals in China, analyzes the potential common problems in the development of radiopharmaceuticals in China through horizontal comparison and vertical analysis, and in combination with the current clinical transformation of small molecular peptide radiopharmaceuticals application research, which has been continuously promoted in varying degrees, this paper analyzes the existing problems in depth, and puts forward the research and development of new radiopharmaceuticals with application prospects and clinical transformation importance and necessity.

关 键 词：放射性药物 创新 临床转化 分子探针 

分 类 号：R817[医药卫生—影像医学与核医学]